top of page
4 days ago

SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like

Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and REGNASE-1 to solve the problem of T-cell exhaustion. The company's first two programs are now in the clinic.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page